Last reviewed · How we verify
GFH375
GFH375 is a small molecule inhibitor of the PI3K delta subunit.
GFH375 is a small molecule inhibitor of the PI3K delta subunit. Used for Moderate to severe ulcerative colitis.
At a glance
| Generic name | GFH375 |
|---|---|
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the PI3K delta subunit, GFH375 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Moderate to severe ulcerative colitis
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer (PHASE3)
- A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation (PHASE1, PHASE2)
- A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations (PHASE1, PHASE2)
- A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GFH375 CI brief — competitive landscape report
- GFH375 updates RSS · CI watch RSS
- Genfleet Therapeutics (Shanghai) Inc. portfolio CI